Kimberly C Paul1, Rebecca Rausch2, Michelle M Creek3, Janet S Sinsheimer3,4, Jeff M Bronstein2, Yvette Bordelon2, Beate Ritz1,2. 1. Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, USA. 2. Department of Neurology, David Geffen School of Medicine, Los Angeles, CA, USA. 3. Department of Biostatistics, UCLA Fielding School of Public Health, Los Angeles, CA, USA. 4. Department of Human Genetics, David Geffen School of Medicine, Los Angeles, CA, USA.
Abstract
BACKGROUND: Cognitive decline is well recognized in Parkinson's disease (PD) and a major concern for patients and caregivers. Apolipoprotein E (APOE), catechol-O-methyl transferase (COMT), and microtubule-associated protein tau (MAPT) are of interest related to their contributions to cognitive decline or dementia in PD. OBJECTIVE: Here, we investigate whether APOE, COMT, or MAPT influence the rate of cognitive decline in PD patients. METHODS: We relied on 634 PD patients and 879 controls to examine gene-PD susceptibility associations, and nested longitudinal cohort of 246 patients from the case-control study, which followed patients on average 5 years and 7.5 years into disease. We repeatedly assessed cognitive symptom progression with the MMSE and conducted a full neuropsychological battery on a subset of 183 cognitively normal patients. We used repeated-measures regression analyses to assess longitudinal associations between genotypes and cognitive progression scores. RESULTS: The MAPT H1 haplotype was associated with PD susceptibility. APOE 4 carriers (ɛ4+) (p = 0.03) and possibly COMT Met/Met (p = 0.06) carriers exhibited faster annual decline on the MMSE. Additionally, APOEɛ4+ carriers showed faster decline in many of the neuropsychological test scores. No such differences in neuropsychological outcomes were seen for the COMT genotypes. CONCLUSION: This work supports a growing set of research identifying overlapping etiology and pathology between synucleinopathies, such as PD, Alzheimer's disease, and tauopathies, especially in the context of cognitive dysfunction in PD. We provide support for the argument that APOE ɛ4+ and COMT Met/Met genotypes can be used as predictors of faster cognitive decline in PD.
BACKGROUND:Cognitive decline is well recognized in Parkinson's disease (PD) and a major concern for patients and caregivers. Apolipoprotein E (APOE), catechol-O-methyl transferase (COMT), and microtubule-associated protein tau (MAPT) are of interest related to their contributions to cognitive decline or dementia in PD. OBJECTIVE: Here, we investigate whether APOE, COMT, or MAPT influence the rate of cognitive decline in PDpatients. METHODS: We relied on 634 PDpatients and 879 controls to examine gene-PD susceptibility associations, and nested longitudinal cohort of 246 patients from the case-control study, which followed patients on average 5 years and 7.5 years into disease. We repeatedly assessed cognitive symptom progression with the MMSE and conducted a full neuropsychological battery on a subset of 183 cognitively normal patients. We used repeated-measures regression analyses to assess longitudinal associations between genotypes and cognitive progression scores. RESULTS: The MAPT H1 haplotype was associated with PD susceptibility. APOE 4 carriers (ɛ4+) (p = 0.03) and possibly COMTMet/Met (p = 0.06) carriers exhibited faster annual decline on the MMSE. Additionally, APOEɛ4+ carriers showed faster decline in many of the neuropsychological test scores. No such differences in neuropsychological outcomes were seen for the COMT genotypes. CONCLUSION: This work supports a growing set of research identifying overlapping etiology and pathology between synucleinopathies, such as PD, Alzheimer's disease, and tauopathies, especially in the context of cognitive dysfunction in PD. We provide support for the argument that APOE ɛ4+ and COMTMet/Met genotypes can be used as predictors of faster cognitive decline in PD.
Authors: Lori A Newkirk; Janise M Kim; Jean M Thompson; Jared R Tinklenberg; Jerome A Yesavage; Joy L Taylor Journal: J Geriatr Psychiatry Neurol Date: 2004-06 Impact factor: 2.680
Authors: Caroline H Williams-Gray; Sarah L Mason; Jonathan R Evans; Thomas Foltynie; Carol Brayne; Trevor W Robbins; Roger A Barker Journal: J Neurol Neurosurg Psychiatry Date: 2013-06-18 Impact factor: 10.154
Authors: Cristina Nombela; James B Rowe; Sophie E Winder-Rhodes; Adam Hampshire; Adrian M Owen; David P Breen; Gordon W Duncan; Tien K Khoo; Alison J Yarnall; Michael J Firbank; Patrick F Chinnery; Trevor W Robbins; John T O'Brien; David J Brooks; David J Burn; Roger A Barker Journal: Brain Date: 2014-07-30 Impact factor: 13.501
Authors: Ignacio F Mata; Catherine O Johnson; James B Leverenz; Daniel Weintraub; John Q Trojanowski; Vivianna M Van Deerlin; Beate Ritz; Rebecca Rausch; Stewart A Factor; Cathy Wood-Siverio; Joseph F Quinn; Kathryn A Chung; Amie L Peterson-Hiller; Alberto J Espay; Fredy J Revilla; Johnna Devoto; Dora Yearout; Shu-Ching Hu; Brenna A Cholerton; Thomas J Montine; Karen L Edwards; Cyrus P Zabetian Journal: Neurobiol Aging Date: 2017-04-20 Impact factor: 4.673
Authors: Albert A Davis; Casey E Inman; Zachary M Wargel; Umber Dube; Brittany M Freeberg; Alexander Galluppi; Jessica N Haines; Dhruva D Dhavale; Rebecca Miller; Fahim A Choudhury; Patrick M Sullivan; Carlos Cruchaga; Joel S Perlmutter; Jason D Ulrich; Bruno A Benitez; Paul T Kotzbauer; David M Holtzman Journal: Sci Transl Med Date: 2020-02-05 Impact factor: 17.956
Authors: Cynthia D J Kusters; Kimberly C Paul; Aline Duarte Folle; Adrienne M Keener; Jeff M Bronstein; Lars Bertram; Johnni Hansen; Steve Horvath; Janet S Sinsheimer; Christina M Lill; Beate R Ritz Journal: Mov Disord Date: 2021-08-23 Impact factor: 9.698
Authors: Kimberly C Paul; Yu-Hsuan Chuang; Myles Cockburn; Jeff M Bronstein; Steve Horvath; Beate Ritz Journal: Sci Total Environ Date: 2018-07-21 Impact factor: 7.963
Authors: Hirotaka Iwaki; Cornelis Blauwendraat; Hampton L Leonard; Jonggeol J Kim; Ganqiang Liu; Jodi Maple-Grødem; Jean-Christophe Corvol; Lasse Pihlstrøm; Marlies van Nimwegen; Samantha J Hutten; Khanh-Dung H Nguyen; Jacqueline Rick; Shirley Eberly; Faraz Faghri; Peggy Auinger; Kirsten M Scott; Ruwani Wijeyekoon; Vivianna M Van Deerlin; Dena G Hernandez; J Raphael Gibbs; Kumaraswamy Naidu Chitrala; Aaron G Day-Williams; Alexis Brice; Guido Alves; Alastair J Noyce; Ole-Bjørn Tysnes; Jonathan R Evans; David P Breen; Karol Estrada; Claire E Wegel; Fabrice Danjou; David K Simon; Ole Andreassen; Bernard Ravina; Mathias Toft; Peter Heutink; Bastiaan R Bloem; Daniel Weintraub; Roger A Barker; Caroline H Williams-Gray; Bart P van de Warrenburg; Jacobus J Van Hilten; Clemens R Scherzer; Andrew B Singleton; Mike A Nalls Journal: Mov Disord Date: 2019-09-10 Impact factor: 9.698